Key result
Review explores the efficacy and limitations of current and emerging LDL-C therapies for familial hypercholesterolemia.
Why the study?
Familial hypercholesterolemia carries increased cardiovascular morbidity and mortality, and the repertoire of pharmacologic agents targeting LDL-cholesterol and cardiovascular disease burden has expanded.
This state-of-the-art review summarizes the development, clinical efficacy, and limitations of current and emerging pharmacotherapies for LDL-cholesterol reduction in familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
Provides FH therapy overview for clinicians; leaves open comparative effectiveness of emerging agents.
Familial hypercholesterolemia is a highly prevalent but underdiagnosed disease marked by increased risk of cardiovascular morbidity and mortality. Aggressive reduction of LDL-cholesterol is a hallmark of cardiovascular risk mitigation in familial hypercholesterolemia. More recently, we have witnessed an expanded repertoire of pharmacologic agents that directly target LDL-cholesterol and/or reduce heart disease burden. In this state-of-the-art review, we explore the development, clinical efficacy and limitations of existing and potential future therapeutics in familial hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Kallapur et al. (2021) conducted a review in Familial hypercholesterolemia. Pharmacotherapy was evaluated. This state-of-the-art review explores the development, clinical efficacy, and limitations of existing and potential future therapeutics for LDL-cholesterol reduction in familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: